Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice

Open access
Greenough, Thomas C., Babcock, Gregory J., Roberts, Anjeanette, Hernandez, Hector J., Thomas, Jr., William D., Coccia, Jennifer A., Graziano, Robert F., Srinivasan, Mohan, Lowy, Israel, Finberg, Robert W., Subbarao, Kanta, Vogel, Leatrice, Somasundaran, Mohan, Luzuriaga, Katherine, Sullivan, John L., Ambrosino, Donna M.·2005·The Journal of Infectious Diseases

Abstract

BACKGROUND: Severe acute respiratory syndrome (SARS) remains a significant public health concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARS-CoV) could provide protection for exposed individuals. METHODS: Transgenic mice with human immunoglobulin genes were immunized with the recombinant major surface (S) glycoprotein ectodomain of SARS-CoV. Epitopes of 2 neutralizing MAbs derived from these mice were mapped and evaluated in a murine model of SARS-CoV infection. RESULTS: Both MAbs bound to S glycoprotein expressed on transfected cells but differed in their ability to block binding of S glycoprotein to Vero E6 cells. Immunoprecipitation analysis revealed 2 antibody-binding epitopes: one MAb (201) bound within the receptor-binding domain at aa 490-510, and the other MAb (68) bound externally to the domain at aa 130-150. Mice that received 40 mg/kg of either MAb prior to challenge with SARS-CoV were completely protected from virus replication in the lungs, and doses as low as 1.6 mg/kg offered significant protection. CONCLUSIONS: Two neutralizing epitopes were defined for MAbs to SARS-CoV S glycoprotein. Antibodies to both epitopes protected mice against SARS-CoV challenge. Clinical trials are planned to test MAb 201, a fully human MAb specific for the epitope within the receptor-binding region.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/427242

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 158

Metadata

Authors
Greenough, T. C., Babcock, G. J., Roberts, A., Hernandez, H. J., Thomas, Jr., Coccia, J. A., Graziano, R. F., Srinivasan, M., Lowy, I., Finberg, R. W., Subbarao, K., Vogel, L., Somasundaran, M., Luzuriaga, K., Sullivan, J. L., & Ambrosino, D. M.
Venue
The Journal of Infectious Diseases
Published
2005-02-15
Volume
191
Issue
4
Pages
507-514
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2096527227
Cited by
158
References
3
FWCI
11.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice. https://app.cochat.ai/papers/10.1086/427242
The paper
Greenough, T. C., Babcock, G. J., Roberts, A., Hernandez, H. J., Thomas, Jr., Coccia, J. A., Graziano, R. F., Srinivasan, M., Lowy, I., Finberg, R. W., Subbarao, K., Vogel, L., Somasundaran, M., Luzuriaga, K., Sullivan, J. L., & Ambrosino, D. M. (2005). Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice. The Journal of Infectious Diseases. https://doi.org/10.1086/427242

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.